IQVIA is paying nearly $200 million to purchase a Myriad Genetics subsidiary that provides pharmaceutical contract services, a deal that will put the new acquisition in the company's Q2 Solutions unit. The deal follows IQVIA's April announcement that it had secured full ownership of Q2, which had been a joint venture with Quest Diagnostics.
Here's a preview of some of the panel discussions at INVEST Precision Medicine, including diagnostics, investment trends, and building a bioinnovation hub.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Salt Lake City-based Myriad Genetics' GeneSight screening analyzes specific genes as a way to predict the effectiveness of 56 common medications for depression.
The grocery chain is offering select Kroger Health Plan members access to Myriad's GeneSight test, which analyzes specific genes as a way to predict the effectiveness of 56 common medications for depression
Just 10 percent of women with a family history of breast cancer test positive for one of the 11 genes directly associated with disease risk. Myriad’s new riskScore assessment caters to the other 90 percent.
Precision oncology is the proof of principle. It’s just a matter of time before such personalized tests and treatments become mainstream in other specialties, from rheumatology to endocrinology to psychiatric care.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Is hereditary cancer screening really worth it for the general population? Increasingly, the answer is 'yes.'
The market leader in cancer panel gene testing flooded the zone at the annual meeting of the American Society of Clinical Oncology in Chicago.
TOP STORIES The Wall Street Journal delivers a pretty solid take on the uncertain future of Myriad Genetics – including a backhand from one of their key competitors. “The whole field of genetic sequencing has been rendered generic,” said Invitae’s chief executive, Randy Scott. “Prices, we think, are going to start coming down fairly dramatically.” […]
Genes can still be patented in Australia, thanks to a recent ruling by the country’s federal court. The court determined last year that companies can patent human genes – particularly Myriad Genetics’ patent on breast cancer-associated gene BRA1 – and on Sept. 5 shot down an appeal that said such a ruling limits genetic testing options […]
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
Update: Despite the U.S. Supreme Court ruling last year year, BRCA gene testing has continued to be an issue in the courts. But a patent infringement case between Myriad Genetics (Nasdaq: MYGN) and GenebyGene has been resolved and offers some guidance on the potential outcome of other cases in which Myriad is embroiled. The terms […]
Myriad Genetics (Nasdaq: MYGN) has acquired Crescendo Bioscience in a $270 million deal. The move helps Myriad move into the autoimmune market. It also adds a mobile and web-based molecular diagnostic platform for rheumatoid arthritis to help patients manage their condition and improve engagement with physicians. It also gives Safeguard (NYSE: SFE) a big exit […]
Even before the Supreme Court ruled on Myriad Genetics yesterday, there was talk in the biotech industry that a decision against the company’s patents would spell bad news for innovation. Trade group BIO is among those expressing concern post-ruling about how young biotechs who have built their business models on DNA patents will fare. Others […]
The Supreme Court ruled yesterday that companies could not patent human genes. This case focused on the BRCA 1 and 2 genes linked to breast cancer risk, but the U.S. Patent Office has issued patents on thousands of human genes, including genes associated with colon cancer, Alzheimer’s disease, and muscular dystrophy. The unanimous decision was […]
No matter how much folks may differ on the implications of the Myriad case, everyone I spoke with or emailed agreed that the U.S. Supreme Court’s unanimous (9-0) ruling means no company can patent human genes isolated from the bloodstream. They also agree that the decision reaffirmed Myriad Genetics’ (NASDAQ: MYGN) right to patent a […]